Ophthalmologists debate whether ectasia is preventable
June 23rd 2008In a point-counterpoint debate at the annual meeting of the American Academy of Ophthalmology, one clinician contended that the rate of post-LASIK ectasia is declining and that, with careful screening and other preparatory steps, the rate of ectasia can be kept very low. The counter-argument by another clinician suggested that the multifactorial basis of ectasia as well as unknown risk factors make it impossible to prevent a certain percentage of cases from developing.
Aspheric IOL offers better contrast sensitivity
June 23rd 2008In a prospective, randomized, contralateral study of 75 adults, eyes in which an aspheric IOL (AcrySof IQ model SN60WF, Alcon Laboratories) had been implanted demonstrated better mesopic contrast sensitivity, significantly less spherical aberration, and significantly less total higher-order aberrations compared with eyes in which a standard spherical IOL (AcrySof model SA60AT, Alcon Laboratories) had been implanted. Cumulative uncorrected visual acuity and best-corrected visual acuity were equivalent between both groups.
Model predicts advanced AMD development
June 18th 2008A new model can predict the percentage of people who will develop advanced age-related macular degeneration (AMD) at various ages. The model, which is based on well-established risk factors for the disease such as age, smoking, and genetics, considers high-risk, intermediate-risk, and low-risk genotypes. Genotypes are more predictive of the risk of developing advanced AMD than is age.
Advanced glycation in diabetic patients leads to cataracts
June 16th 2008The higher level of advanced glycation end products (AGE) in senile diabetic patients may correlate to a higher rate of cataract development, according to a study published in the May?June 2008 issue of the Journal of Diabetes and its Complications.
Multifocal IOLs in glaucoma patients
June 16th 2008Further study is needed to establish the role of multifocal IOLs in eyes with glaucomatous damage, according to Ike Ahmed, MD, who was speaking during the glaucoma subspecialty day at the annual meeting of the American Society of Cataract and Refractive Surgery.
Allergan to cash in on eyelash stimulant effect of glaucoma drug
June 13th 2008Following positive clinical trial results, Allergan, the makers of bimatoprost, are submitting a new drug application (NDA) to the US Food and Drug Administration (FDA), seeking a new indication for the prostaglandin analogue as an eyelash growth stimulant.
FA and OCT work best in combination
June 13th 2008Although fluorescein angiography (FA) and optical coherence tomography (OCT) are both effective ways to detect macular oedema (ME), when used in isolation they may miss subtle manifestations of the condition, according to a study published in the April 2008 issue of Retina.
Avastin decreases PCV symptoms
June 13th 2008Intravitreal injections of bevacizumab (Avastin; Genentech) stabilize vision and decrease retinal detachment in patients with polypoidal choroidal vasculopathy (PCV), according to a study published in the May 2008 issue of the British Journal of Ophthalmology.
Combination therapies go head to head
June 6th 2008Azarga (brinzolamide 1%/timolol 0.5% eye drops suspension; Alcon) and Cosopt (dorzolamide 2%/timolol 0.5% eye drops solution; Merck) are equally efficacious in IOP-lowering capacity, however, Azarga offers greater ocular comfort, according to a study presented at this week?s European Glaucoma Society congress in Berlin, Germany.